2023 World Conference on Lung Cancer (Posters)-EP11.02. Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC

EP11.02. Rh-endostatin Combined With PD-1 inhibitors as First-line Treatment for EGFR/ALK-Negative, Non-squamous NSCLC - PDF(Abstract)

Back to course

Pdf Summary

The study presented at WCLC 2023 aimed to evaluate the effectiveness and safety of combining Rh-endostatin, PD-1 inhibitors, and chemotherapy as a first-line treatment for EGFR/ALK-negative, non-squamous non-small cell lung cancer (NSCLC). The study was conducted in China and included 90 patients.<br /><br />The results showed that in the cohort receiving Rh-endostatin, PD-1 inhibitors, and chemotherapy, the objective response rate (ORR) was 57.7% and the disease control rate (DCR) was 88.5%. The median progression-free survival (PFS) was 16.7 months. In the cohort not receiving PD-1 inhibitors, the ORR was 34.2% and the DCR was 84.2%, with a median PFS of 16.4 months.<br /><br />The majority of adverse events (AEs) were grade 1 or 2, with the most common grade 3 or higher AEs being neutropenia, leukopenia, and anemia. The overall incidence of AEs was similar between the two cohorts.<br /><br />The study concluded that the combination of Rh-endostatin with PD-1 inhibitors showed promising clinical outcomes and tolerable toxicity for EGFR/ALK-negative, non-squamous NSCLC. This treatment regimen could be a potential first-line option for this patient population.<br /><br />In summary, the study demonstrated that combining Rh-endostatin, PD-1 inhibitors, and chemotherapy as a first-line treatment for EGFR/ALK-negative, non-squamous NSCLC resulted in an objective response rate of 57.7% and a disease control rate of 88.5%, with a median progression-free survival of 16.7 months. The combination therapy showed favorable clinical outcomes and manageable adverse events, suggesting its potential as a promising treatment option.

Asset Subtitle

Dong Wang

Meta Tag

Speaker Dong Wang

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

WCLC 2023

Rh-endostatin

PD-1 inhibitors

chemotherapy

first-line treatment

EGFR/ALK-negative

non-squamous NSCLC

objective response rate

disease control rate

progression-free survival